论文部分内容阅读
一九八○年十月十七日在四川省乐山市长征制药厂召开了新药异了基哌嗪力复霉素(R-76-1)临床科研交流会。会议期间重点交流了新药R76-1在抗结核和抗麻风以及其它感染性疾病的临床试用情况。 一、治疗结核病方面:参加临床科研共18个单位,疗程满三个月共315例,其中男195例,女120例。 (一)治疗效果: 1.痰结核菌的改变:治疗前痰结核菌集菌或厚涂片全部阳性。治疗三个月时转阴初治组90/142例为63.38％,复治组129/173为74.57％。 2.X线检查结果: i)病灶改变:病灶吸收好转总有效率初治组122/142例为85.91％,复治组130/173例为75.14％。 ii)空洞改变:315例有空洞213个。空
On October 17, 1980, a new Rifampicin (R-76-1) clinical scientific exchange meeting was held at Changzheng Pharmaceutical Factory in Leshan City, Sichuan Province. The meeting focused on the clinical trial of new drug R76-1 for anti-TB and anti-leprosy as well as other infectious diseases. First, the treatment of tuberculosis: to participate in clinical research a total of 18 units, a course of three months a total of 315 cases, including 195 males and 120 females. (A) the treatment effect: 1. The change of sputum TB: sputum tuberculosis bacteria before treatment or thick smear all positive. Three months after treatment, 90/142 cases of negative initial treatment group was 63.38%, and the recovery group 129/173 was 74.57%. 2.X-ray examination results: i) lesion change: the improvement of lesion absorption total effective rate of 122/142 initial treatment group was 85.91%, retreatment group 130/173 cases were 75.14%. ii) Void changes: 315 cases have 213 holes. air